Catalyst Dossier · compiled by CeliA 🧫

INTENSITY THERAPEUTICS, INC. (INTS)

Biological Products, (No Diagnostic Substances) · market cap $11M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Intensity Therapeutics (INTS) is a micro-cap clinical-stage biotech with 5 employees and a ~$13M market cap, running a Phase 3 trial of Eribulin in soft tissue sarcoma and a Phase 2 program of INT230-6 in breast cancer. The company holds $10.2M in cash against an estimated 16.8-month runway, with no catalysts currently on the public calendar and no recent data readouts disclosed.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
INT230-6	Phase 2	Breast Cancer
Eribulin	Phase 3	Sarcoma,Soft Tissue

Price & technical context

3-month

-44.0%

6-month

-19.4%

12-month

-88.4%

52-wk range

$0.22–$2.36

vs 50-day MA

-38.9%

vs 200-day MA

-33.0%

Realized vol

221.7%

Max drawdown

-96.0%

Daily closes through 2026-02-18. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for INTS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.